Microbial Drug Resistance

Microbial Drug Resistance (MDR) is an international, peer-reviewed journal that covers the global threat and spread of multi-drug resistant clones of major pathogens that are widely documented in hospitals and the scientific community, the efforts to develop novel therapeutic strategies targeting the drug-resistant bacteria, reinforcing the barrier-effect of the microbiome and host directed responses.

The Journal also addresses the serious challenges of trying to decipher the molecular mechanisms of drug resistance, the dissemination of resistance between strains and species, and what we can learn from it to block the process.

MDR provides a multidisciplinary forum for peer-reviewed original and novel publications under four distinct formats:

1. Original Research Articles that describe in detail novel observations
2. Short Reports that briefly describe unique and novel observations
3. Review Articles that highlight the state-of-the-art in a particular field
4. Opinion Pieces, Commentaries and Perspectives on a particularly timely and impactful topic

Papers that describe only small incremental work will not be considered for peer review and publication.

MDR coverage includes:

• Molecular biology of resistance mechanisms
• Mechanisms of resistance dissemination and emergence
• Molecular epidemiology of resistance
• Reservoirs of resistance and antimicrobial genes
• Targeting virulence genes and disease mechanisms
• Drug design and screening
• Novel natural products screens and anti-biotherapy
• Novel Therapies
• Host directed strategies
• Infection control and stewardship

Microbial Drug Resistance is under the editorial leadership of Editor-in-Chief Ivo G. Boneca, PhD, Research Director, DRI, INSERM. View the entire editorial board.

Audience: Molecular biologists, cell biologists, viral immunologists, microbiologists, viral infection pathologists, among others